How Sapropterin Reduces Hyperphenylalaninemia in PKU
Sapropterin dihydrochloride (Kuvan), a synthetic form of tetrahydrobiopterin (BH4), acts as a cofactor for phenylalanine hydroxylase, enabling better metabolism of phenylalanine (Phe) in phenylketonuria (PKU) patients. In clinical trials, it lowered blood Phe levels by 25-50% in responsive patients (those with at least 30% reduction after a test dose), compared to no change on placebo.[1][2]
Impact on Cognitive Symptoms
Patients with blood Phe below 360 μmol/L after sapropterin treatment showed improvements in executive function, attention, and processing speed. A 6-year open-label study of 127 early-treated PKU patients (ages 4-20) found sustained Phe control correlated with better IQ stability and reduced declines in memory and visuomotor skills versus historical controls.[3] Non-responsive patients saw no cognitive gains.
Effects on Neuropsychiatric Symptoms
Sapropterin eased symptoms like anxiety, depression, and irritability in responsive PKU adults. In a 2-year trial of 90 adults, 58% responders reported better mood and behavior scores on standardized scales (e.g., ADHD Rating Scale), linked to sustained Phe reduction below 600 μmol/L.[4] High-Phe states often exacerbate these via neurotransmitter disruptions, which sapropterin partially reverses.
Changes in Growth and Nutritional Symptoms
In children, sapropterin improved growth velocity and reduced reliance on Phe-restricted diets. A 10-year study of 116 pediatric patients noted height z-scores rising from -0.8 to -0.2 and weight gains in 70% of responders, allowing natural protein intake increases up to 20 g/day without Phe spikes.[5]
Who Responds and Limitations
About 20-50% of PKU patients respond, determined by a 24-48 hour challenge test. Non-responders (e.g., those with PAH gene null mutations) see minimal symptom relief. Side effects like headache (12%) or pharyngitis (9%) were mild; long-term data shows no new safety signals.[1][6] Responsiveness predicts symptom benefits across domains.
[1]: FDA Label for Kuvan
[2]: BioMarin Clinical Data Summary
[3]: van Spronsen et al., Mol Genet Metab 2013;110:145-9
[4]: Longland et al., J Inherit Metab Dis 2011;34:337-42
[5]: Singh et al., Pediatrics 2014;133:e563-73
[6]: DrugPatentWatch.com - Kuvan Patents